Free Trial

Piper Sandler Has Lowered Expectations for InspireMD (NYSE:NSPR) Stock Price

InspireMD logo with Medical background

InspireMD (NYSE:NSPR - Get Free Report) had its target price lowered by investment analysts at Piper Sandler from $4.50 to $4.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an "overweight" rating on the stock. Piper Sandler's price objective would indicate a potential upside of 69.49% from the stock's previous close.

Separately, StockNews.com assumed coverage on shares of InspireMD in a report on Monday, May 5th. They issued a "sell" rating for the company.

Get Our Latest Stock Analysis on NSPR

InspireMD Trading Down 0.4%

Shares of NSPR traded down $0.01 during mid-day trading on Monday, reaching $2.36. The company's stock had a trading volume of 38,992 shares, compared to its average volume of 37,431. The stock has a market cap of $72.30 million, a PE ratio of -3.15 and a beta of 0.62. InspireMD has a 52 week low of $2.07 and a 52 week high of $3.80. The company's fifty day moving average price is $2.62 and its two-hundred day moving average price is $2.74.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in NSPR. Affiance Financial LLC increased its stake in shares of InspireMD by 2.9% in the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company's stock worth $497,000 after buying an additional 5,376 shares during the period. Legato Capital Management LLC purchased a new position in shares of InspireMD in the fourth quarter worth $47,000. Essex Investment Management Co. LLC purchased a new position in shares of InspireMD in the fourth quarter worth $191,000. Renaissance Technologies LLC purchased a new position in shares of InspireMD in the fourth quarter worth $27,000. Finally, Northern Trust Corp increased its stake in shares of InspireMD by 103.7% in the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company's stock worth $126,000 after buying an additional 24,452 shares during the period. 44.78% of the stock is owned by hedge funds and other institutional investors.

About InspireMD

(Get Free Report)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.

Featured Stories

Should You Invest $1,000 in InspireMD Right Now?

Before you consider InspireMD, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InspireMD wasn't on the list.

While InspireMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Congress Is Pouring Millions Into These 6 Surprising Stocks
3 Dirt-Cheap Stocks in a Market That’s Getting Expensive
Top 3 Defense Stocks to Profit From $175 Billion Golden Dome

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines